Hikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Rating of “Buy” from Brokerages

Hikma Pharmaceuticals PLC (LON:HIK) has received an average recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is GBX 2,085.83.

HIK has been the subject of a number of recent research reports. Citigroup boosted their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Jefferies Financial Group lifted their price target on shares of Hikma Pharmaceuticals from GBX 1,870 to GBX 2,025 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Finally, Berenberg Bank upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research note on Tuesday, August 11th.

Hikma Pharmaceuticals Price Performance

Shares of Hikma Pharmaceuticals stock opened at GBX 1,599 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The firm has a market capitalization of £3.34 billion, a PE ratio of 8.83, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. The business’s 50-day moving average price is GBX 1,596.47 and its 200-day moving average price is GBX 1,463.06. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 1,865.

Insiders Place Their Bets

In other Hikma Pharmaceuticals news, insider Tobias Hestler purchased 7,500 shares of the stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.04% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.